Literature DB >> 11454066

Interleukin-12 primes CD4+ T cells for interferon-gamma production and protective immunity during Mycobacterium avium infection.

R A Silva1, M Flórido, R Appelberg.   

Abstract

Interleukin-12 (IL-12) is a crucial cytokine for the generation of a protective immune response against Mycobacterium avium infection. In contrast to infected control mice, IL-12-deficient mice were unable to control bacterial proliferation and their spleen T cells were almost unresponsive in vitro to specific antigens of M. avium. Susceptibility of mice deficient in IL-12 was similar to that of interferon-gamma (IFN-gamma)-deficient mice. These data indicate a crucial role of IL-12 in the development of a T-cell population able to produce IFN-gamma and to mediate protection against M. avium infection. Treatment of M. avium-infected mice with IL-12 induced CD4+ T cells with enhanced capacity to produce IFN-gamma as well as to confer increased protection against M. avium.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454066      PMCID: PMC1783245          DOI: 10.1046/j.1365-2567.2001.01237.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  51 in total

1.  Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells.

Authors:  B Perussia; S H Chan; A D'Andrea; K Tsuji; D Santoli; M Pospisil; D Young; S F Wolf; G Trinchieri
Journal:  J Immunol       Date:  1992-12-01       Impact factor: 5.422

Review 2.  Mycobacterium avium complex infection in the acquired immunodeficiency syndrome.

Authors:  C R Horsburgh
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

3.  Natural history of disseminated Mycobacterium avium complex infection in AIDS.

Authors:  M A Jacobson; P C Hopewell; D M Yajko; W K Hadley; E Lazarus; P K Mohanty; G W Modin; D W Feigal; P S Cusick; M A Sande
Journal:  J Infect Dis       Date:  1991-11       Impact factor: 5.226

4.  Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor).

Authors:  M K Gately; B B Desai; A G Wolitzky; P M Quinn; C M Dwyer; F J Podlaski; P C Familletti; F Sinigaglia; R Chizonnite; U Gubler
Journal:  J Immunol       Date:  1991-08-01       Impact factor: 5.422

Review 5.  Mycobacterial diseases other than tuberculosis.

Authors:  E Wolinsky
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

6.  Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients.

Authors:  S D Nightingale; L T Byrd; P M Southern; J D Jockusch; S X Cal; B A Wynne
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

7.  Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends.

Authors:  J A Havlik; C R Horsburgh; B Metchock; P P Williams; S A Fann; S E Thompson
Journal:  J Infect Dis       Date:  1992-03       Impact factor: 5.226

8.  Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy.

Authors:  C R Horsburgh; J A Havlik; D A Ellis; E Kennedy; S A Fann; R E Dubois; S E Thompson
Journal:  Am Rev Respir Dis       Date:  1991-09

9.  Infection with Mycobacterium avium complex in patients without predisposing conditions.

Authors:  D S Prince; D D Peterson; R M Steiner; J E Gottlieb; R Scott; H L Israel; W G Figueroa; J E Fish
Journal:  N Engl J Med       Date:  1989-09-28       Impact factor: 91.245

10.  Role of gamma interferon and tumor necrosis factor alpha during T-cell-independent and -dependent phases of Mycobacterium avium infection.

Authors:  R Appelberg; A G Castro; J Pedrosa; R A Silva; I M Orme; P Minóprio
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

View more
  12 in total

1.  Gamma interferon-induced T-cell loss in virulent Mycobacterium avium infection.

Authors:  Manuela Flórido; John E Pearl; Alejandra Solache; Margarida Borges; Laura Haynes; Andrea M Cooper; Rui Appelberg
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

2.  Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds.

Authors:  Capucine Picard; Claire Fieschi; Frédéric Altare; Suliman Al-Jumaah; Sami Al-Hajjar; Jacqueline Feinberg; Stéphanie Dupuis; Claire Soudais; Ibrahim Zaid Al-Mohsen; Emmanuelle Génin; David Lammas; Dinakantha S Kumararatne; Tony Leclerc; Arash Rafii; Husn Frayha; Belinda Murugasu; Lee Bee Wah; Raja Sinniah; Michael Loubser; Emi Okamoto; Abdulaziz Al-Ghonaium; Haysam Tufenkeji; Laurent Abel; Jean-Laurent Casanova
Journal:  Am J Hum Genet       Date:  2001-12-17       Impact factor: 11.025

Review 3.  Pathogenesis of Mycobacterium avium infection: typical responses to an atypical mycobacterium?

Authors:  Rui Appelberg
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

4.  Virulence and immune response induced by Mycobacterium avium complex strains in a model of progressive pulmonary tuberculosis and subcutaneous infection in BALB/c mice.

Authors:  Mónica González-Pérez; Leonardo Mariño-Ramírez; Carlos Alberto Parra-López; Martha Isabel Murcia; Brenda Marquina; Dulce Mata-Espinoza; Yadira Rodriguez-Míguez; Guillermina J Baay-Guzman; Sara Huerta-Yepez; Rogelio Hernandez-Pando
Journal:  Infect Immun       Date:  2013-08-19       Impact factor: 3.441

5.  High dose interleukin-12 exacerbates Bordetella pertussis infection and is associated with suppression of cell-mediated immunity in a murine aerosol challenge model.

Authors:  C R D Carter; B M Dagg; K M Whitmore; J R Keeble; C Asokanathan; D Xing; K B Walker
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

6.  The combination of plasmid interleukin-12 with a single DNA vaccine is more effective than Mycobacterium bovis (bacille Calmette-Guèrin) in protecting against systemic Mycobacterim avium infection.

Authors:  Ela Martin; Arun T Kamath; Helen Briscoe; Warwick J Britton
Journal:  Immunology       Date:  2003-06       Impact factor: 7.397

7.  Heme catabolism by heme oxygenase-1 confers host resistance to Mycobacterium infection.

Authors:  Sandro Silva-Gomes; Rui Appelberg; Rasmus Larsen; Miguel Parreira Soares; Maria Salomé Gomes
Journal:  Infect Immun       Date:  2013-04-29       Impact factor: 3.441

8.  Limited role of the Toll-like receptor-2 in resistance to Mycobacterium avium.

Authors:  M Salomé Gomes; Manuela Flórido; João V Cordeiro; C Miguel Teixeira; Osamu Takeuchi; Shizuo Akira; Rui Appelberg
Journal:  Immunology       Date:  2004-02       Impact factor: 7.397

9.  Activation of an NLRP3 inflammasome restricts Mycobacterium kansasii infection.

Authors:  Chang-Chieh Chen; Sheng-Hui Tsai; Chia-Chen Lu; Shiau-Ting Hu; Ting-Shu Wu; Tsung-Teng Huang; Najwane Saïd-Sadier; David M Ojcius; Hsin-Chih Lai
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

10.  Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: medical and immunological implications.

Authors:  Claire Fieschi; Stéphanie Dupuis; Emilie Catherinot; Jacqueline Feinberg; Jacinta Bustamante; Adrien Breiman; Frédéric Altare; Richard Baretto; Françoise Le Deist; Samer Kayal; Hartmut Koch; Darko Richter; Martin Brezina; Guzide Aksu; Phil Wood; Suliman Al-Jumaah; Miquel Raspall; Alberto José Da Silva Duarte; David Tuerlinckx; Jean-Louis Virelizier; Alain Fischer; Andrea Enright; Jutta Bernhöft; Aileen M Cleary; Christiane Vermylen; Carlos Rodriguez-Gallego; Graham Davies; Renate Blütters-Sawatzki; Claire-Anne Siegrist; Mohammad S Ehlayel; Vas Novelli; Walther H Haas; Jacob Levy; Joachim Freihorst; Sami Al-Hajjar; David Nadal; Dewton De Moraes Vasconcelos; Olle Jeppsson; Necil Kutukculer; Klara Frecerova; Isabel Caragol; David Lammas; Dinakantha S Kumararatne; Laurent Abel; Jean-Laurent Casanova
Journal:  J Exp Med       Date:  2003-02-17       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.